- Conditions
- Autonomic Failure, Orthostatic Hypotension
- Interventions
- Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Medullary Thyroid Cancer
- Interventions
- vandetanib, omeprazole, ranitidine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- Selpercatinib, Ranitidine, Omeprazole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Rabeprazole ER, Ranitidine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Moline, Illinois
- Conditions
- Myeloma
- Interventions
- Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
- Drug · Other
- Lead sponsor
- Robert Redner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 22
- States / cities
- Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
- Conditions
- Pharmacokinetics
- Interventions
- Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Rabeprazole ER, Ranitidine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Moline, Illinois
- Conditions
- Healthy
- Interventions
- lesinurad 400 mg, ranitidine 150 mg, lesinurad 400 mg + ranitidine 150 mg
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Cypress, California